FeesSafety
Pluang+

Moderna stock surges 545% in 2026, investors face choice to take profits or hold for pipeline growth.

Market News
06 Oct 2026, 22:03 WIB
24/7 Wall Street
View Source
Bullish
Moderna stock surges 545% in 2026, investors face choice to take profits or hold for pipeline growth.

Moderna's stock has soared 545% year-to-date, driven by its mRNA technology and a promising oncology pipeline including a personalized cancer vaccine. The company now joins the NASDAQ 100, increasing its visibility and institutional interest. Despite strong gains, investors must weigh locking in profits against the risks and potential of Moderna's developing treatments. The stock's rapid rise outpaces peers like BioNTech and Pfizer, highlighting the need for careful portfolio management.

As of Oct 07, 2026 02:21 WIB, Moderna (MRNA) trades at USD 189.95, close to its 52-week high of USD 203.46 but down 6.53% on the day, contrasting with Pfizer (PFE) which is near its 52-week high at USD 27.48 and up 0.26%. BioNTech (BNTX) remains below its 52-week peak at USD 96.22, down 1.45%, while Moderna's market cap of $81.13B is significantly smaller than Pfizer's $156.23B. On Pluang, Moderna sees a strong buy interest at 76%, compared to Pfizer's 29% buy activity.

More News (MRNA)

Moderna jumps 5% on surprise Q3 profit and raised 2026 revenue outlook, driven by strong vaccine sales.

Moderna jumps 5% on surprise Q3 profit and raised 2026 revenue outlook, driven by strong vaccine sales.

Moderna reported a surprise Q3 2026 profit of $0.38 per share versus an expected loss, with revenue rising to $1.31 billion due to strong international COVID-19 vaccine demand. The company raised its 2026 revenue growth forecast to 15-25% and expects...

Company Fundamentals
Bullish
1 day ago
Moderna stock soars 700% on cancer vaccine hopes but earnings show Covid vaccines still drive revenue

Moderna stock soars 700% on cancer vaccine hopes but earnings show Covid vaccines still drive revenue

Moderna's stock price has surged 700% this year amid excitement over its experimental cancer vaccine. However, the company's recent earnings reveal that its revenue growth remains largely driven by strong international demand for its Covid vaccines. ...

Company Fundamentals
Bullish
1 day ago
Moderna raises 2026 revenue growth forecast to up to 25%, boosting stock.

Moderna raises 2026 revenue growth forecast to up to 25%, boosting stock.

Moderna increased its revenue outlook for 2026, now expecting growth between 15% and 25%, up from a previous forecast of 10%. The company, known for its mRNA COVID-19 vaccine Spikevax, cited strong sales as the reason for the optimistic update. This ...

Company Fundamentals
Bullish
1 day ago
Moderna beats Q3 estimates, raises 2026 revenue growth forecast to 15-25%.

Moderna beats Q3 estimates, raises 2026 revenue growth forecast to 15-25%.

Moderna exceeded third-quarter revenue and earnings expectations, reporting $1.31 billion in revenue and 38 cents earnings per share, compared to analyst estimates of $885.1 million and a loss of $1.25 per share. The company raised its 2026 revenue g...

Company Fundamentals
Bullish
1 day ago
Moderna, Humana, and Elanco earnings reports on Nov 6 will test recent stock rallies amid key healthcare trends.

Moderna, Humana, and Elanco earnings reports on Nov 6 will test recent stock rallies amid key healthcare trends.

On November 6, Moderna, Humana, and Elanco will release earnings reports that could impact their stock rallies. Humana's Medicare Advantage update is crucial for retirees, with a focus on medical costs and membership trends. Elanco faces supply chall...

Company Fundamentals
Neutral
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App